Clinica Viedma

Viedma R8500ACE

1 studies enrolling now · 6 studies all time

What they study most

Advanced Melanoma, Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), Metastatic Head and Neck Cancer, PD-L1 Negative, PD-L1 Positive, Recurrent Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Unresectable Head and Neck Squamous Cell Carcinoma

Studies at this site

• A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 — Recruiting now
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) — Recruiting now
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling
• Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) — Running, not enrolling
• A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) — Stopped early
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer — Running, not enrolling